Skip to contentT
Travere Therapeutics, Inc.
T
TVTXTravere Therapeutics, Inc. Q4 2017 · 10-K
Revenue$42.18M$42.18M+13.0% vs Q4 2016 Net Income-$17.62M-$17.62MN/M vs Q4 2016 EPS Diluted-$0.55-$0.55N/M vs Q4 2016 Operating Income-$15,177,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Travere Therapeutics, Inc. · CIK 1438533 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$304,000N/M Margins · derivedOperating margin-36.0%+12.8 pt vs Q4 2016
Net margin-41.8%−18.7 pt vs Q4 2016
ended Dec 31, 2017 · filed Feb 27, 2018 · 58 d after period end